TY - JOUR T1 - Phytochemical Analysis, Network Pharmacology and in Silico Investigations on Anacamptis pyramidalis Tuber Extracts. AU - Mahomoodally,Mohamad Fawzi, AU - Picot-Allain,Marie Carene Nancy, AU - Zengin,Gokhan, AU - Llorent-Martínez,Eulogio J, AU - Abdullah,Hassan H, AU - Ak,Gunes, AU - Senkardes,Ismail, AU - Chiavaroli,Annalisa, AU - Menghini,Luigi, AU - Recinella,Lucia, AU - Brunetti,Luigi, AU - Leone,Sheila, AU - Orlando,Giustino, AU - Ferrante,Claudio, Y1 - 2020/05/22/ PY - 2020/04/16/received PY - 2020/05/15/revised PY - 2020/05/20/accepted PY - 2020/5/28/entrez PY - 2020/5/28/pubmed PY - 2021/2/17/medline KW - Anacamptis pyramidalis KW - antioxidant KW - docking study KW - enzyme inhibition KW - network pharmacology KW - phytochemical fingerprint JF - Molecules (Basel, Switzerland) JO - Molecules VL - 25 IS - 10 N2 - Anacamptis pyramidalis (L.) Rich. forms part of the Orchidaceae family that is highlyvalued for its horticultural as well as therapeutic benefits. The present study set out to investigatethe inhibitory activity of A. pyramidalis tubers against key biological targets for the management oftype 2 diabetes, Alzheimer disease, and skin hyperpigmentation. In addition, the antioxidantpotential of the extracts was also assessed using multiple methods. The detailed phytochemicalprofiles of the extracts were determined using high-performance liquid chromatography. Based onqualitative phytochemical fingerprint, a network pharmacology analysis was conducted as well.Parishin was identified from the water extract only, whereas gastrodin and caffeic acid derivativeswere present in the methanol extract. The methanol extract exhibited high inhibitory activityagainst tyrosinase (69.69 mg kojic acid equivalent/g extract), α-amylase (15.76 mg acarboseequivalent/g extract), and α-glucosidase (20.07 mg acarbose equivalent/g extract). Similarly, themethanol extract showed highest antioxidant potential (22.12, 44.23, 45.56, and 29.38 mg Troloxequivalent/g extract, for 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), CUPric Reducing Antioxidant Capacity (CUPRAC),and Ferric Reducing Antioxidant Power (FRAP) assays, respectively). Finally, the results ofnetwork pharmacology analysis, besides corroborating traditional uses of plant extracts in themanagement of cold and flu, confirmed a direct involvement of identified phytochemicals in theobserved enzyme inhibitory effects, especially against tyrosinase, α-amylase, and α-glucosidase.Furthermore, based on the results of both colorimetric assays and network pharmacology analysis related to the activity of A. pyramidalis extracts and identified phytocompounds on enzymesinvolved in type 2 diabetes, a docking study was conducted in order to investigate the putativeinteractions of oxo-dihydroxy octadecenoic acid trihydroxy octadecenoic acid against aldosereductase, peroxisome proliferator-activated receptor (PPAR)-α, dipeptidyl peptidase (DPP)-IV,and α-glucosidase. Docking analysis suggested the inhibitory activity of these compounds againstthe aforementioned enzymes, with a better inhibitory profile shown by oxo-dihydroxyoctadecenoic acid. Overall, the present findings supported the rationale for the use of A.pyramidalis as source of bioactive metabolites and highlight, today more than ever, for the strongnecessity of linkage strategy between wild resource valorization and conservation policy. SN - 1420-3049 UR - https://www.unboundmedicine.com/medline/citation/32455936/Phytochemical_Analysis_Network_Pharmacology_and_in_Silico_Investigations_on_Anacamptis_pyramidalis_Tuber_Extracts_ DB - PRIME DP - Unbound Medicine ER -